HealthCor Catalio Acquisition Corp.
HCAQ
NASDAQ Capital Market10.92
USD
+0.49
- -
Return %
Stock
S&P500
1Y
- -
26.53
3Y
- -
76.60
5Y
- -
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 55 Hudson Yards New York City NY United States of America 10001
- IPO Date
- Jan 27, 2021
- Website
- hcspac.com
- Similar Companies
- Business
- HealthCor Catalio Acquisition Corp. HealthCor Catalio Acquisition Corp. operates as a blank check company, or special purpose acquisition company (SPAC), with no significant ongoing business operations and focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, primarily targeting companies in the healthcare industry, including life sciences and medical technology sectors in the United States and other developed countries. The company holds cash in trust derived from its initial public offering and concurrent private placement proceeds; offers redeemable shares, warrants, and rights to public shareholders; and provides specific governance services such as de-registration upon consummation of a business combination, continuation votes, and mandatory liquidations if no initial combination occurs within specified timeframes. Incorporated in 2020, HealthCor Catalio Acquisition Corp. maintains its headquarters in New York, New York, and historically concentrated on healthcare innovators without disclosing additional subsidiaries or parent relationships. In its key transaction, HealthCor Catalio Acquisition Corp. completed a reverse merger business combination on December 22, 2021, with Hyperfine, Inc., the developer of the Swoop portable MRI system, and Liminal Sciences, Inc., a brain sensing technology firm, resulting in the combined entity trading under the Nasdaq ticker HYPR as Hyperfine, Inc., with gross proceeds of approximately $160 million and a pro forma enterprise value of around $580 million supported by a $126 million PIPE from investors including HealthCor Management LP, Catalio Capital Management, Perceptive Advisors, and others. Subsequent to the merger, the original SPAC structure ceased active independent operations as Hyperfine, Inc. advanced its portable MRI platform with developments such as FDA clearances for next-generation Swoop systems powered by Optive AI software in May and June 2025, CE Mark and UKCA approvals for global expansion, a $17.5 million public offering in October 2025, new clinical studies like PRISM PMR for operating room use, and distribution partnerships in Europe, the Middle East, and India. No further standalone activities, acquisitions, funding rounds, or strategic shifts for HealthCor Catalio Acquisition Corp. appear post-merger, aligning with typical SPAC lifecycle completion.
Portable MRI Device Maker Hyerfine Going Public Via SPAC: What Investors Should Know
Hyperfine, Inc., Creator of the First FDA-Cleared Portable MRI Device, and Liminal Sciences, Inc. To Be Listed on Nasdaq Through a Business Combination With HealthCor Catalio Acquisition Corp.
HealthCor Catalio Acquisition Corp. Announces Closing of Upsized $207 Million Initial Public Offering